<?xml version="1.0" encoding="UTF-8"?>
<p>Although MM remains generally incurable despite recent treatment advances, patient outcomes, including progression‐free survival (PFS) and overall survival (OS), have improved, and thanks to improved regimens and the increasing number of active treatment options, MM is becoming more of a chronic condition for many patients, with increasing 10‐year survival rates (Pulte 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0039" ref-type="ref">2011</xref>; Barlogie 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0002" ref-type="ref">2014</xref>; Katodritou 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0023" ref-type="ref">2016</xref>). An associated development is that treatment strategies are substantially moving towards continuous, long‐term therapeutic approaches, which have been shown to improve patient outcomes compared with fixed‐duration therapy options (Benboubker 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0005" ref-type="ref">2014</xref>; Palumbo 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0037" ref-type="ref">2014</xref>, 
 <xref rid="bjh15394-bib-0038" ref-type="ref">2015</xref>; Guglielmelli &amp; Palumbo, 
 <xref rid="bjh15394-bib-0015" ref-type="ref">2015</xref>; Katodritou 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0023" ref-type="ref">2016</xref>). In this context, there is a need for additional active, safe and convenient regimens that are feasible for long‐term administration, offer reduced patient burden and maintain quality of life (Baz 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0004" ref-type="ref">2015</xref>; Guglielmelli &amp; Palumbo, 
 <xref rid="bjh15394-bib-0015" ref-type="ref">2015</xref>; Dowling 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0010" ref-type="ref">2016</xref>; Delforge &amp; Ludwig, 
 <xref rid="bjh15394-bib-0009" ref-type="ref">2017</xref>).
</p>
